Regulated information

ThromboGenics has in total 35,691,432 shares outstanding

Leuven, Belgium – 3 April 2012 – ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that, as the result of the exercise of warrants by a number of the Company's employees and the private placement announced on 28 March 2012, ThromboGenics now has a total of 35,691,432 shares outstanding and listed on NYSE Euronext Brussels.

On 28 October 2011, 33,000 new shares were created as a result of a warrants exercise. On 3 April 2012, 3,244,675 new shares were created in the context of the private placement, raising €77.8 million.

- Ends -

For further information please contact:

Chris Buyse, CFO	Tel: + 32 16 75 13 10 chris.buyse@thrombogenics.com
Citigate Dewe Rogerson David Dible/ Nina Enegren/ Sita Shah	Tel: +44 (0) 207 638 9571 nina.enegren@citigatedr.co.uk

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company's lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (VMA). The MAA for ocriplasmin has been accepted for review in Europe and the BLA will be re-submitted in the U.S. by April 2012. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon's net sales of ocriplasmin. ThromboGenics and Alcon intend to share the costs equally of developing ocriplasmin for a number of new vireoretinal indications.

ThromboGenics is also developing two novel antibody therapeutics in collaboration with BioInvent International. These are TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF), in Phase Ib/II for cancer which has been partnered with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. These forward-looking statements may be identified by references to strategy, plans, objectives, goals, future events or intentions. Forward-looking statements may and often do differ materially from actual results. The company therefore cannot provide any assurance that such forward-looking statements will materialize. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the company's annual report.

ThromboGenics N.V., Gaston Geenslaan 1, B-3001 Leuven, Belgium
tel +32 (0)16 75 13 10 fax +32 (0)16 75 13 11
BTW/VAT BE 0881.620.924, RPR Leuven
www.thrombogenics.com